Therapy: Risk of metformin use in patients with T2DM and advanced CKD.
In a new study published in The Lancet Diabetes & Endocrinology, metformin use is associated with significantly increased all-cause mortality in patients with type 2 diabetes mellitus and stage 5 chronic kidney disease (CKD). The findings support current recommendations that metformin should not be used in patients with stage 5 CKD.
Rudolfstiftung Hospital, Department of Medicine 1, Juchgasse 25, 1030 Vienna, Austria.
Guntram
G
Schernthaner
Clinical Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Marie Helene
MH
Schernthaner-Reiter
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008687:Metformin / Q000009:adverse effects*; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000401:mortality*
D007004:Hypoglycemic Agents; D008687:Metformin